Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy

Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy

Background: Systemic Lutetium-177 prostate-specific membrane antigen-617 radioligand therapy (Lu-177-PSMA-617-RLT) is a novel treatment approach in patients suffering from metastasized castration-resistant prostate cancer. Nonetheless, a therapeutic response may fail to appear in a proportion of pat...

Full description

Bibliographic Details
Main Authors: Caliebe, A. (Author), Jüptner, M. (Author), Lützen, U. (Author), Marx, M. (Author), Osmonov, D. (Author), Wrenger, R. (Author), Zhao, Y. (Author), Zuhayra, M. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
Lu-177-PSMA-617
Radioligand therapy, castration-resistant prostate cancer
Survival analysis
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items